Filing Flows › Companies › Immunocore Holdings › Timeline
Immunocore Holdings stock timeline
A year of the price with every insider trade, planned sale, earnings report and material 8-K marked
252 sessions−1.9% to $30.99
Immunocore Holdings (IMCR) stock fell 2% over the last 252 sessions, to $30.99. On the way it reported 5 quarters, its insiders filed 4 open-market trades, and the company filed 2 material 8-Ks. Each is marked on the price and listed with what the stock did next.
Each mark, and what followed
| Date | Kind | What | Next session | 5 sessions | 21 sessions |
|---|---|---|---|---|---|
| Nov 6, 2026 | Earnings | Earnings: missed the EPS estimate by -107.3% | +8.7% (+8.4% vs SPY) | — | — |
| Aug 6, 2026 | Earnings | Earnings: missed the EPS estimate by -195.6% | +3.6% (+3.7% vs SPY) | +4.3% (+3.9% vs SPY) | +12.1% (+11.7% vs SPY) |
| May 6, 2026 | Earnings | Earnings: beat the EPS estimate by 196.5% | +6.3% (+5.0% vs SPY) | +1.6% (−0.4% vs SPY) | −0.3% (−4.8% vs SPY) |
| Feb 25, 2026 | Earnings | Earnings: missed the EPS estimate by -196.0% | −4.6% (−5.5% vs SPY) | −4.0% (−3.0% vs SPY) | −10.6% (−6.3% vs SPY) |
| Feb 18, 2026 | Insider sale | St Leger Tina Amber sold $32K | +0.4% (−0.1% vs SPY) | +3.9% (+3.3% vs SPY) | −7.5% (−4.3% vs SPY) |
| Feb 18, 2026 | Insider sale | Jallal Bahija sold $371K | +0.4% (−0.1% vs SPY) | +3.9% (+3.3% vs SPY) | −7.5% (−4.3% vs SPY) |
| Feb 18, 2026 | Insider sale | Goll John sold $23K | +0.4% (−0.1% vs SPY) | +3.9% (+3.3% vs SPY) | −7.5% (−4.3% vs SPY) |
| Feb 18, 2026 | Insider sale | Berman David M sold $193K | +0.4% (−0.1% vs SPY) | +3.9% (+3.3% vs SPY) | −7.5% (−4.3% vs SPY) |
| Jan 30, 2026 | 8-K | Directors and officers: departures, appointments, pay | −1.4% (−1.1% vs SPY) | −6.5% (−4.1% vs SPY) | −1.0% (+0.1% vs SPY) |
| Nov 28, 2025 | 8-K | Directors and officers: departures, appointments, pay | −1.6% (−2.1% vs SPY) | +0.2% (−0.5% vs SPY) | −12.6% (−14.1% vs SPY) |
| Nov 6, 2025 | Earnings | Earnings: beat the EPS estimate by 100.0% | +2.6% (+3.6% vs SPY) | +13.6% (+12.8% vs SPY) | +23.1% (+21.9% vs SPY) |
Insiders’ record here
In the year on the chart, Immunocore Holdings' insiders reported 0 open-market buys ($0) and 4 sales ($619K). Of the 4 old enough to score, 4 were followed by the stock doing what the trade implied over the next 63 sessions (beating SPY after a buy, lagging it after a sale); the median excess return after a buy was — and after a sale −17.9%.
Across the whole universe (19,782 scored trades), insider buys beat the market 46% of the time and sales were followed by a lagging stock 61% of the time; buys of $1M or more 39%. Every pattern →
What this kind of 8-K usually did
| Item | 8-Ks | Next session, median | Up next session | 21 sessions, median | Typical size |
|---|---|---|---|---|---|
| 5.02 Directors and officers: departures, appointments, pay | 39,174 | −0.1% | 48% | +0.7% | ±1.4% |
Across every company in the move-odds universe, measured from the close before the filing. Every 8-K item ranked →
Report card: every quarter against the estimate → Immunocore Holdings: every quarter → Live insider trades →
Prices are daily closes; filings and trades are as filed with the SEC (Form 4 within two business days of the trade, 8-K within four of the event). Moves after a mark are the stock's close-to-close change and the same for SPY; they describe the record, not what the next one will do. Not investment advice.